ViewRay, Inc. (VRAY)
(Delayed Data from NSDQ)
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay Allies With Two Majors in MR-Guided Radiation Therapy
by Zacks Equity Research
ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.
Options Traders Expect Huge Moves in ViewRay (VRAY) Stock
by Zacks Equity Research
Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 22.22% and 0.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?
by Zacks Equity Research
Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.
What's in the Cards for Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
In Spine & CMF, Zimmer Biomet (ZBH) is witnessing slowdown in growth due to difficult comps.
Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
What's in the Offing for LabCorp's (LH) Earnings in Q3?
by Zacks Equity Research
LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.
Are Options Traders Betting on a Big Move in ViewRay (VRAY) Stock?
by Zacks Equity Research
Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in ViewRay (VRAY) Stock?
by Zacks Equity Research
Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -39.13% and 12.57%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -54.55% and -3.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ViewRay (VRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, ViewRay (VRAY) closed at $7.72, marking a -0.13% move from the previous day.
ViewRay (VRAY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
ViewRay (VRAY) closed at $7.39 in the latest trading session, marking a -0.4% move from the prior day.
ViewRay (VRAY) Stock Moves -1.59%: What You Should Know
by Zacks Equity Research
In the latest trading session, ViewRay (VRAY) closed at $8.37, marking a -1.59% move from the previous day.
Fluidigm (FLDM) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.